Patents Assigned to Avir Green Hills Biotechnology Research Development Trade AG
  • Publication number: 20130183740
    Abstract: The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus which comprises at least one amino acid modification within the N-terminal cyto plasmic region of the NA protein.
    Type: Application
    Filed: June 6, 2011
    Publication date: July 18, 2013
    Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
    Inventors: Thomas Muster, Andrej Egorov, Markus Wolschek
  • Publication number: 20120237527
    Abstract: Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.
    Type: Application
    Filed: April 19, 2012
    Publication date: September 20, 2012
    Applicant: Avir Green Hills Biotechnology Research Development Trade AG
    Inventors: Klaus Wolff, Hubert Pehamberger, Andreas Grassauer, Thomas Muster
  • Publication number: 20110268764
    Abstract: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.
    Type: Application
    Filed: May 3, 2011
    Publication date: November 3, 2011
    Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
    Inventors: Monika Sachet, Michael Bergmann, Thomas Muster, Andrej Egorov
  • Publication number: 20110262481
    Abstract: The present invention provides a high growth reassortant influenza A virus having at least two gene segments of seasonal or pandemic strain origin, a PB1 gene segment of A/Texas/1/77 strain origin and a PA gene segment of A/Puerto Rico/8/34 (H1N1) origin coding for a PA protein comprising at least one amino acid modification at any one of positions 10, 275, 682, according to SEQ ID No.1. Further provided are vaccine formulations comprising the reassortant influenza A virus of the invention.
    Type: Application
    Filed: December 18, 2009
    Publication date: October 27, 2011
    Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
    Inventors: Thomas Muster, Markus Wolschek, Andrej Egorov, Elisabeth Roethl, Julia Romanova, Michael Bergmann
  • Publication number: 20110250587
    Abstract: The present invention provides a method for generating negative-stranded segmented RNA viruses using linear expression constructs in the presence of helper virus.
    Type: Application
    Filed: December 3, 2009
    Publication date: October 13, 2011
    Applicant: Avir Green Hills Biotechnology Research Development Trade AG
    Inventors: Thomas Muster, Andrej Egorov, Markus Wolschek
  • Publication number: 20110223199
    Abstract: The present invention provides a method for producing pH-stable enveloped viruses wherein said viruses are used for infection of host cells under low pH conditions and for incubation with cell culture cells under conditions of low pH, as well as influenza viruses obtainable by this method which exhibit a high growth rate in cell culture, increased pH and temperature stability and which have human receptor specificity.
    Type: Application
    Filed: November 25, 2009
    Publication date: September 15, 2011
    Applicant: AVIR GREEN HILLS BIOTECHNOLOGY RESEARCH DEVELOPMENT TRADE AG
    Inventors: Julia Romanova, Andrej Egorov, Brigitte Krenn, Markus Wolschek, Sabine Nakowitsch
  • Patent number: 8008460
    Abstract: Nucleotide sequences and fragments which code for a human endogenous retrovirus which is infectious. “Fragments” according to the present invention relate also to specific fragments of the sequences inserted into the vector pCR4-Topo and deposited as MERV-env, MERV-gag, MERV-prt and MERV-pol as mentioned above. Additionally, methods of using such sequences, polypeptides encoded by such sequences, antibodies directs against such sequences, and methods and compositions relating to the same are all contemplated.
    Type: Grant
    Filed: October 30, 2008
    Date of Patent: August 30, 2011
    Assignee: Avir Green Hills Biotechnology Research Development Trade AG
    Inventors: Klaus Wolff, Hubert Pehamberger, Andreas Grassauer, Thomas Muster
  • Publication number: 20100184191
    Abstract: The present invention provides a method for generating negative-strand, segmented RNA viruses using linear expression constructs in the presence of helper virus.
    Type: Application
    Filed: December 3, 2009
    Publication date: July 22, 2010
    Applicant: AVIR Green Hills Biotechnology Research Development Trade AG
    Inventors: Thomas MUSTER, Andrej EGOROV, Markus WOLSCHEK
  • Publication number: 20100136052
    Abstract: The present invention covers a novel replication deficient influenza virus comprising a modified NS1 segment coding for a NS1 protein lacking a functional RNA binding domain and functional effector domain and a heterologous sequence inserted between the splice donor site and the splice acceptor site of the NS gene segment. Further the use of the virus as vector for expression of various proteins like chemokines, cytokines or antigenic structures is covered, methods for producing virus particles using said virus vector as well as its use for production of vaccines. Also a fusion peptide comprising part of the N-terminus of an NS1 protein and a signal sequence fused to the C-terminus of said NS1 peptide is covered.
    Type: Application
    Filed: June 26, 2008
    Publication date: June 3, 2010
    Applicant: AVIR Green Hills Biotechnology Research Development Trade AG
    Inventors: Markus Wolschek, Andrej Egorov, Michael Bergmann, Thomas Muster, Christian Kittel
  • Publication number: 20100129399
    Abstract: The present invention provides a linear expression construct free of any conventional amplification and/or selection sequences comprising an RNA polymerase I (polI) promoter and a polI termination signal, inserted between a RNA polymerase II (polII) promoter and a polyadenylation signal useful for the expression of segments of viral RNA, preferably influenza viruses. The inventive construct is useful for efficient and fast production of viral particles, especially for producing vaccine formulations for the treatment of epidemic and/or pandemic diseases.
    Type: Application
    Filed: June 26, 2008
    Publication date: May 27, 2010
    Applicant: AVIR Green Hills Biotechnology Research Development Trade AG
    Inventors: Markus Wolschek, Andrej Egorov, Michael Bergmann, Thomas Muster, Christian Kittel
  • Publication number: 20100003221
    Abstract: The use of macrolide polyene antibiotics or derivatives or analogues thereof as culture supplement for the propagation of virus is described. Further pharmaceutical compositions comprising a virus and a macrolide polyene antibiotic or a derivative or analogue thereof and methods for using of macrolide polyene antibiotics for transfection and infection of cells as well as the use of macrolide poylene antibiotics for the isolation of virus from clinical samples are disclosed.
    Type: Application
    Filed: October 11, 2007
    Publication date: January 7, 2010
    Applicant: AVIR Green Hills Biotechnology Research Development Trade AG
    Inventors: Elisabeth Röthl, Andrej Egorov
  • Publication number: 20090130129
    Abstract: The present invention provides antigenic polypeptides derived from the melanoma-associated endogenous retrovirus (MERV). These antigens are useful compounds for the detection of cancerous cells and melanoma-diagnosis as well as melanoma-prognosis. Furthermore these antigenic polypeptides of the present invention form the basis for anti-cancer vaccines.
    Type: Application
    Filed: May 11, 2006
    Publication date: May 21, 2009
    Applicant: Avir Green Hills Biotechnology Research Development Trade AG
    Inventors: Bernd Mayer, Johannes Humer, Thomas Muster, Andrea Waltenberger
  • Publication number: 20090123495
    Abstract: The present invention provides a pharmaceutical composition with an adjuvant based on an apathogenic virus, together with an antigen. The adjuvant has a natural or through genetical engineering no, reduced or altered expression of an endogenous interferon antagonist or endogenous immune suppressor.
    Type: Application
    Filed: August 8, 2006
    Publication date: May 14, 2009
    Applicant: Avir Green Hills Biotechnology Research Development Trade AG
    Inventors: Monika Sachet, Michael Bergmann, Thomas Muster, Andrej Egorov
  • Patent number: 7510862
    Abstract: Described is a polynucleotide molecule being a fragment of a polynucleotide sequence of an infectious human endogenous retrovirus, said polynucleotide molecule comprising a sequence selected from the group consisting of (a) a sequence with at least 98%, preferably 99%, still preferred 99.5%, identity to a sequence according to SEQ ID No 1, (b) a sequence which hybridises under stringent conditions with a nucleotide sequence according to said SEQ ID No 1, (c) a sequence which differs from said sequences (a) or (b) due to degeneration of the genetic code and (d) a sequence comprising sequences inserted into vectors pCR4-Topo and deposited as “MERV-env”, “MERV-gag”, “MERV-prt” and “MERV-pol” at the DSMZ on 26 Sep. 2001 or fragments thereof.
    Type: Grant
    Filed: September 27, 2002
    Date of Patent: March 31, 2009
    Assignee: Avir Green Hills Biotechnology Research Development Trade AG
    Inventors: Klaus Wolff, Hubert Pehamberger, Andreas Grassauer, Thomas Muster